Related references
Note: Only part of the references are listed.Effectiveness and safety of oral anticoagulants in elderly patients with atrial fibrillation
Ole-Christian Walter Rutherford et al.
HEART (2022)
Comparing risk of major bleeding between users of different oral anticoagulants in patients with nonvalvular atrial fibrillation
Patrick C. Souverein et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2021)
Clinical outcomes of nonvitamin K oral anticoagulants and acenocoumarol for stroke prevention in contemporary practice: A population-based propensity-weighted cohort study
Clara L. Rodriguez-Bernal et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2021)
2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)
Gerhard Hindricks et al.
EUROPEAN HEART JOURNAL (2021)
Safety of Dabigatran as an Anticoagulant: A Systematic Review and Meta-Analysis
Ya Zhou et al.
FRONTIERS IN PHARMACOLOGY (2021)
Dose specific effectiveness and safety of DOACs in patients with non-valvular atrial fibrillation: A Canadian retrospective cohort study
Elham Rahme et al.
THROMBOSIS RESEARCH (2021)
Effectiveness safety and costs of stroke prevention in non-valvular auricular fibrillation. Study of cohorts matched by Propensity score
Maria Giner-Soriano et al.
ATENCION PRIMARIA (2020)
Reduced dose of rivaroxaban and dabigatran vs. vitamin K antagonists in very elderly patients with atrial fibrillation in a nationwide cohort study
Laurent Fauchier et al.
EUROPACE (2020)
Safety and Effectiveness of Dabigatran and Other Direct Oral Anticoagulants Compared With Warfarin in Patients With Atrial Fibrillation
Krista F. Huybrechts et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2020)
Early Dabigatran Treatment After Transient Ischemic Attack and Minor Ischemic Stroke Does Not Result in Hemorrhagic Transformation
Anas Alrohimi et al.
CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES (2020)
Switching warfarin to direct oral anticoagulants in atrial fibrillation: Insights from the NCDR PINNACLE registry
Christopher T. Sciria et al.
CLINICAL CARDIOLOGY (2020)
Patients' perceptions with dabigatran in patients with atrial fibrillation previously treated with vitamin K antagonists
Vivencio Barrios et al.
JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH (2020)
Inappropriate dose of nonvitamin-K antagonist oral anticoagulants: prevalence and impact on clinical outcome in patients with nonvalvular atrial fibrillation
Cosmo Godino et al.
JOURNAL OF CARDIOVASCULAR MEDICINE (2020)
Comparing stroke prevention therapy of direct oral anticoagulants and vitamin K antagonists in patients with atrial fibrillation: a nationwide retrospective observational study
Lena M. Paschke et al.
BMC MEDICINE (2020)
Randomized controlled clinical trials versus real-life atrial fibrillation patients treated with oral anticoagulants. Do we treat the same patients?
Pawel Balsam et al.
CARDIOLOGY JOURNAL (2020)
A comprehensive appraisal of dabigatran etexilate clinical evidence and applications: a 10-year-long story
Giulio Francesco Romiti et al.
FUTURE CARDIOLOGY (2020)
Stroke prevention in atrial fibrillation changes after dabigatran availability in China: The GLORIA-AF registry
Changsheng Ma et al.
JOURNAL OF ARRHYTHMIA (2020)
Heart Disease and Stroke Statistics-2019 Update A Report From the American Heart Association
Emelia J. Benjamin et al.
CIRCULATION (2019)
Comparisons between Oral Anticoagulants among Older Nonvalvular Atrial Fibrillation Patients
Steven Deitelzweig et al.
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY (2019)
Comparative effectiveness and safety of low-strength and high-strength direct oral anticoagulants compared with warfarin: a sequential cohort study
Nicole L. Pratt et al.
BMJ OPEN (2019)
Effectiveness and safety of direct oral anticoagulants compared to warfarin in treatment naive non-valvular atrial fibrillation patients in the US Department of defense population
Kiran Gupta et al.
BMC CARDIOVASCULAR DISORDERS (2019)
Effectiveness and safety of 110 or 150 mg dabigatran vs. vitamin K antagonists in nonvalvular atrial fibrillation
Patrick Blin et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2019)
Comparative risks of bleeding, ischemic stroke and mortality with direct oral anticoagulants versus phenprocoumon in patients with atrial fibrillation
Mariam Ujeyl et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2018)
Risk of Myocardial Infarction in Anticoagulated Patients With Atrial Fibrillation
Christina Ji-Young Lee et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)
Dabigatran, rivaroxaban and apixaban vs. high TTR warfarin in atrial fibrillation
Sara Sjalander et al.
THROMBOSIS RESEARCH (2018)
Risks and benefits of direct oral anticoagulants versus warfarin in a real world setting: cohort study in primary care
Yana Vinogradova et al.
BMJ-BRITISH MEDICAL JOURNAL (2018)
Risks and benefits of direct oral anticoagulants versus warfarin in a real world setting: cohort study in primary care
Yana Vinogradova et al.
BMJ-BRITISH MEDICAL JOURNAL (2018)
Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study
Peter Bronnum Nielsen et al.
BMJ-BRITISH MEDICAL JOURNAL (2017)
Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study
Peter Bronnum Nielsen et al.
BMJ-BRITISH MEDICAL JOURNAL (2017)
Sex-Specific Associations of Oral Anticoagulant Use and Cardiovascular Outcomes in Patients With Atrial Fibrillation
Ghanshyam Palamaner Subash Shantha et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2017)
Epidemiology and Management of Atrial Fibrillation and Stroke: Review of Data from Four European Countries
Andreea D. Ceornodolea et al.
STROKE RESEARCH AND TREATMENT (2017)
A nationwide registry study to compare bleeding rates in patients with atrial fibrillation being prescribed oral anticoagulants
Sigrun Halvorsen et al.
EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY (2017)
Real-world evidence of stroke prevention in patients with nonvalvular atrial fibrillation in the United States: the REVISIT-US study
Craig I. Coleman et al.
CURRENT MEDICAL RESEARCH AND OPINION (2016)
Bleeding in patients with atrial fibrillation treated with dabigatran, rivaroxaban or warfarin: A retrospective population-based cohort study
Martin H. Ellis et al.
EUROPEAN JOURNAL OF INTERNAL MEDICINE (2016)
'Real-world' haemorrhagic rates for warfarin and dabigatran using population-level data in New Zealand
Prasad S. Nishtala et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2016)
Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin A propensity score matched analysis
Gregory Y. H. Lip et al.
THROMBOSIS AND HAEMOSTASIS (2016)
ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions
Jonathan A. C. Sterne et al.
BMJ-BRITISH MEDICAL JOURNAL (2016)
Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study
Torben Bjerregaard Larsen et al.
BMJ-BRITISH MEDICAL JOURNAL (2016)
ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions
Jonathan A. C. Sterne et al.
BMJ-BRITISH MEDICAL JOURNAL (2016)
Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study
Torben Bjerregaard Larsen et al.
BMJ-BRITISH MEDICAL JOURNAL (2016)
Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation
Xiaoxi Yao et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2016)
Rayyan-a web and mobile app for systematic reviews
Mourad Ouzzani et al.
SYSTEMATIC REVIEWS (2016)
Comparison of the Short-Term Risk of Bleeding and Arterial Thromboembolic Events in Nonvalvular Atrial Fibrillation Patients Newly Treated With Dabigatran or Rivaroxaban Versus Vitamin K Antagonists A French Nationwide Propensity-Matched Cohort Study
Geric Maura et al.
CIRCULATION (2015)
Sex Differences in Dabigatran Use, Safety, And Effectiveness In a Population-Based Cohort of Patients With Atrial Fibrillation
Meytal Avgil Tsadok et al.
CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES (2015)
Sex Differences in Dabigatran Use, Safety, And Effectiveness In a Population-Based Cohort of Patients With Atrial Fibrillation
Meytal Avgil Tsadok et al.
CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES (2015)
Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement
David Moher et al.
SYSTEMATIC REVIEWS (2015)
Cardiovascular, Bleeding, and Mortality Risks in Elderly Medicare Patients Treated With Dabigatran or Warfarin for Nonvalvular Atrial Fibrillation
David J. Graham et al.
CIRCULATION (2015)
Bleeding Events Among New Starters and Switchers to Dabigatran Compared with Warfarin in Atrial Fibrillation
Torben Bjerregaard Larsen et al.
AMERICAN JOURNAL OF MEDICINE (2014)
Stroke prevention in atrial fibrillation: An Asian perspective
Chern-En Chiang et al.
THROMBOSIS AND HAEMOSTASIS (2014)
Use of Antithrombotic Therapy According to CHA2DS2-VASc Score in Patients With Atrial Fibrillation in Primary Care
Vivencio Barrios et al.
REVISTA ESPANOLA DE CARDIOLOGIA (2014)
Edoxaban versus Warfarin in Patients with Atrial Fibrillation
Robert P. Giugliano et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
The nuts and bolts of PROSPERO: an international prospective register of systematic reviews
Alison Booth et al.
SYSTEMATIC REVIEWS (2012)
Apixaban versus Warfarin in Patients with Atrial Fibrillation
Christopher B. Granger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
Manesh R. Patel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Newly Identified Events in the RE-LY Trial
Stuart J. Connolly et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Dabigatran versus Warfarin in Patients with Atrial Fibrillation.
Stuart J. Connolly et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Share Paper
